



DOI: <https://doi.org/10.56936/18290825-2026.20v.2-56>

EVALUATING THE EFFECTS OF CIGARETTE SMOKING AND HEATED TOBACCO PRODUCTS ON THE ORAL MUCOSA AND PERIODONTIUM IN PATIENTS WITH HEPATITIS C VIRUS IN ARMENIA: A PILOT STUDY

AZATYAN V.YU.^{1*}, YESSAYAN L.K.¹, SHMAVONYAN M.V.², MURADYAN A.A.³

¹ Department of Therapeutic Stomatology, Yerevan State Medical University, Yerevan, Armenia

² Department of Infection Diseases, Yerevan State Medical University, Yerevan, Armenia

³ Department of Urology and Andrology, Yerevan State Medical University, Yerevan, Armenia

Received 01.10.2025; Accepted for printing 14.05.2026

ABSTRACT

Since the last decades of the twentieth century, there has been an increase in the incidence of hepatitis C virus. Currently, diseases of the oral mucosa and periodontium are an important problem in dentistry. Interest in the study of combined pathology in recent years is explained by the accumulation of new facts, such as cigarette smoking and harmful chemicals released during smoking, which have a negative impact on the health of the oral cavity. Tobacco consumption is a global public health problem. In addition, in recent years, new types of products such as heated tobacco products have emerged that are marketed as a means of harm reduction, it is important to note that in Heated Tobacco Products products, the tobacco is not directly burned. The aim of this study is to evaluate the impact of cigarette smoking and heated tobacco products on the oral mucosa and periodontium in patients with hepatitis C virus. The study included 192 patients with hepatitis C virus, who were divided into groups: Cigarette smoking with Hepatitis C virus infection (main group, n= 96) and control group Hepatitis C virus infection using heated tobacco products n=96. The average age of patients was 52.05 ± 12.25. A clinical examination of the oral cavity, including the status of the oral mucosa and periodontium, was conducted. Hemorrhages on the buccal mucosa and hard palate were detected in 92.7% of the examined Cigarette smoking with Hepatitis C virus infection patients (p<0.001). Hyperemia and edema of the gums were observed with a high degree of reliability (p<0.001) in the group of patients with Cigarette smoking with Hepatitis C virus infection. Abundant growth of microorganisms was observed in almost all patients in the Smokers with Hepatitis C virus infection group. *P. gingivalis* was cultured 89.1%, *T. forsythia* 93.5%; *E. corrodens* 87% and *A. actinomycetemcomitans* 95.7% cases which had a statistically significant difference (p<0.001) in data compared to the heated tobacco users with Hepatitis C virus infection group. Thus, the oral mucosa and periodontium status of Hepatitis C virus infection patients using the Heated Tobacco Products system were significantly better than that of the patients Hepatitis C virus infection smoking cigarettes. In the Cigarette smoking with Hepatitis C virus infection group, periodontopathogenic microorganisms were observed in 100% of pathological gingival pockets cases. Further studies with larger sample sizes are needed to better understand the oral health of hepatitis C virus patients.

KEYWORDS: Oral mucosa, periodontium, Hepatitis C virus infection (HCVI), cigarette smoking, heated tobacco products (HTPs), heated tobacco users with Hepatitis C virus infection (HHCV).

CITE THIS ARTICLE AS:

AZATYAN V.YU., YESSAYAN L.K., SHMAVONYAN M.V., MURADYAN A.A. (2026). Evaluating the Effects of Cigarette Smoking and Heated Tobacco Products on the Oral Mucosa and Periodontium in Patients with Hepatitis C virus in Armenia: A Pilot Study; 2026.20v.2-56

ADDRESS FOR CORRESPONDENCE:

Vahe Yu. Azatyan, PhD, DMS, MD, Professor
Department of Therapeutic Stomatology Yerevan State
Medical University after M. Heratsi
2 Koryn Street, Yerevan 0025, Armenia
Tel.: (+374) 91 32-67-73
E-mail: vahe.azatyan@gmail.com

INTRODUCTION

Since the last decades of the twentieth century, there has been an increase in the incidence of Hepatitis C virus infection (HCVI) [Azatyan VYu et al., 2022]. According to World Health Organization (WHO), 71 million people are chronically infected with Hepatitis C virus infection [WHO, 2025]. Currently, diseases of the oral mucosa and periodontium are an important problem in dentistry. This is due to the widespread prevalence of oral mucosa and periodontal lesions, the diversity of nosological forms and their relationship with systemic pathologies, difficulties in diagnosis and treatment, the success of which depends on the correctness of the diagnosis [Iglesias-Sancho M et al., 2020; Luo Z et al., 2020]. Interest in the study of combined pathology in recent years is explained by the accumulation of new facts, such as cigarette smoking and harmful chemicals released during smoking, which have a negative impact on the health of the oral cavity. Tobacco consumption is a global public health problem as more than a billion people from different ethnic groups and socioeconomic backgrounds smoke across the planet, with high prevalence of tobacco use observed in low- and middle-income countries [Neuberger J, 2021; Le Foll B et al., 2022; Ankily MA et al., 2024]. Tobacco consumption remains one of the most widespread health problems of humanity, causing millions of deaths every year, as its use is associated with a wide range of health complications such as lung cancer, cardiovascular diseases, respiratory diseases and oral health problems [Varghese J, Gharde PM, 2023; Ankily MA et al., 2024].

Despite the fact that cigarette smoking (CS) is one of the most common habits that have a negative impact on health, the advertising strategies of tobacco companies have contributed to its widespread use [Nazir MA et al., 2019; Owens VL et al., 2019]. In addition, in recent years, new types of products such as heated tobacco products (HTPs) have emerged that are marketed as a means of harm reduction [Saravia I, Pisinger C, 2020; Kim SC, Friedman TC, 2022]. It is important to note that in HTPs products, the tobacco is not directly burned. The temperature applied to the tobacco varies from ambient temperature to 330 °C - 350 °C, depending on the device [Willemsen MC et al., 2015; Vukas J et al., 2023]. Heated tobacco products produce less sidestream smoke and less toxic combustion products than heated cigarettes, resulting in a reduction in chronic diseases

associated with traditional smoking such as lung cancer, coronary heart disease, and chronic obstructive pulmonary disease [Znyk M et al., 2021]. The long-term risks of these alternatives remain controversial as the main harmful compounds are present in tobacco smoke emissions [Ratajczak A et al., 2020; Upadhyay S et al., 2023]. New hazards continue to emerge as the consumption of these alternative smoking methods continues to spread among populations around the world [Znyk M et al., 2021; Luca A-C et al., 2023]. Their effectiveness in promoting smoking cessation remains largely uncertain, and their impact on smoking initiation among young people is a matter of debate [Czoli CD et al., 2020; Camoni N et al., 2023].

Both forms of tobacco are associated with oral mucosa and periodontal diseases, with cigarette smoking worsening gingival health, increasing total gram-negative anaerobes due to chronic tissue hypoxia induced by nicotine, decreasing tissue blood flow, reducing the immune response to infections, increasing the release of inflammatory mediators due to frequent exposure to harmful and potentially harmful products from smoking, and impairing gingival healing [Komar K et al., 2018; Jiang X et al., 2019; Zhang Y et al., 2019; Pouly S et al., 2021; Silva H, 2021; Yoshioka T, Tabuchi T, 2021]. Cigarette smoking has been associated with benign mucosal diseases including periodontal diseases such as gingivitis [Johnson NW et al., 2000; Calsina G et al., 2002; Moimaz SAS et al., 2009].

Since cigarette smoking enters the body through the oral cavity, proper functioning of the oral epithelium is important as a first defense and requires a balance between proliferation, differentiation and desquamation or death of its cells [Zanetti F et al., 2016].

Although cigarette smoking exposure did not affect the cell cycle in oral keratinocytes, it altered the numbers of cells with early and late apoptotic features, indicating effects on oral epithelial biology [Sever E et al., 2023]. Moreover, smoking leads to xerostomia, decreased saliva production, and decreased salivary self-cleansing and acid-buffering capacity [Kakoei S et al., 2021].

Saliva is a complex biological fluid consisting of various electrolytes, peptides, glycoproteins, lipids and water. Its functions include protection of the oral mucosa, digestion, taste sensations and maintaining pH balance. It is the first biological fluid to come into

contact with tobacco, which causes structural and functional changes in it, expressed in a decrease in its quantity. The main component of tobacco is nicotine, which can stimulate taste buds, some cholinergic receptors, and blood flow to the salivary glands, causing changes in salivary secretion. Mechanical, chemical, and thermal stimulation of the salivary glands by cigarettes during smoking can cause a short-term increase in saliva. Some studies have shown a short-term increase in salivation as a result of stimulation, but the long-term impact of tobacco use remains unclear [Petrušić N et al., 2015; Saputri D et al., 2017].

There is evidence that long-term smoking is one of the external factors that reduces saliva production and causes hyposalivation. Hyposalivation can be caused by many factors, such as salivary gland diseases, various organic diseases, chemotherapy, radiation therapy, and can also be a side effect of various drugs [Kauss AR et al., 2022; Kopa PN et al., 2020]. Cigarette smokers often experience subjective feelings of xerostomia and halitosis. These oral health consequences highlight the importance of individual awareness of smoking-related complications and seeking support for smoking cessation to maintain oral health [Myagmar-Ochir E et al., 2021]. In addition, cigarette smoking significantly worsens liver damage and increases the risk of liver cancer in people with Hepatitis C virus infection by promoting fibrosis and interacting with the effects of the virus. This combination creates a multiplicative risk of liver cancer, and smokers with Hepatitis C virus infection often experience worse health outcomes. Therefore, concurrent tobacco cessation treatment and Hepatitis C virus infection treatment are critical to maximise health benefits and prevent severe complications of chronic liver disease [Cohen JF et al., 2024].

Similarly, heated tobacco products, although perceived as a potentially less harmful alternative to traditional cigarettes, may also cause oral changes [Haiduc A et al., 2020; Ye P et al., 2021]. In addition, the heat generated by heating tobacco may damage oral organs by reducing saliva production and contributing to more intense lesions [Patil PB et al., 2013].

Consumption of heated tobacco products and cigarette smoking, although somewhat different in mechanisms and consequences, have a significant impact on oral health [Wiesmann-Imilowski, N et al., 2024]. Based on the above, we consider it appropriate to conduct this study.

The aim of this study is to evaluate the impact of cigarette smoking and heated tobacco products on the oral mucosa and periodontium in patients with viral hepatitis C.

MATERIAL AND METHODS

The study included 192 patients with Hepatitis C virus infection, who were divided into groups (Group I patients with main group (n= 96) cigarette smokers with HCV infection (SHCV)), Group II - patients with Hepatitis C virus infection using heated tobacco products (HHCV) n=96 (control group)). The average age of patients was 52.05 ± 12.25 (mean ± SD), hospitalized in the period 2024-2025 in the infectious diseases clinic "Mikaelyan Institute of Surgery" Yerevan State Medical University (Yerevan, Armenia), 129 (67.2%) men and 63 (32.8%) women. The final diagnosis of Hepatitis C virus infection was established based on the detection of hepatitis C virus Ribonucleic acid (RNA) in the blood by polymerase chain reaction (PCR).

To assess the condition of the oral cavity and periodontium, a clinical examination was conducted, including an external examination of the corners of the mouth, an assessment of the condition of various areas of the OM and periodontium (color, relief, presence of pathological elements, consistency, bleeding, pathological gingival pockets, dental plaque), as well as the condition of the tongue (color, plaque, foci of epithelial desquamation).

Microbiological study: Microbiological studies were conducted from the pathological gingival pockets in 92 patients with Hepatitis C virus infection. The material for the microbiological study was gingival fluid taken with sterile paper points from the pathological gingival pockets. The points were immersed in test tubes with 5 ml of nutrient broth and delivered to the laboratory for examination no later than 2 hours after taking the material. Microscopy was performed on the original material to assess the overall picture of the microflora. The diluted samples were seeded by the drop method on selective and differential diagnostic media: Endo agar, Chocolate agar, Sabouraud medium, 5% blood agar - (Casein Soybean Digest Agar with neutralizer and Tryptic Soy Agar with Lecithin and Tween. Lecithin, Tween®, UNSPSC Code: 41106231; Columbia agar with 5% Sheep Blood, Catalogue Numbers 63784, 12016409. Corporate

Headquarters: Bio-Rad Laboratories Inc. 1000 Alfred Nobel Drive Hercules, CA 94547 USA; Legal Entity / Contact Address: Bio-Rad Laboratories Pty Ltd u1A, 62 Ferndell Street, South Granville NSW2142 Australia). The incubation mode of microorganisms on dense selective and differential diagnostic media was adopted as follows: for Endo agar medium - 37 °C for 24 hours, Sabouraud - 37 °C - 48 - 72 hours, blood agar - 37 °C - 24 - 48 hours, respectively. For an approximate assessment of the quantitative growth of microorganisms in the association, it is advisable to use the following criteria: 104 -105 - moderate growth; 106 -108 - abundant growth (indicate a pathological process).

Study of cytokines in oral fluid (OF): Cytokines of the oral fluid were tested among 75 patients with HCVI. The test material was unstimulated mixed saliva – oral fluid, obtained without stimulation and collected with a sterile syringe into steril tubes. Samples were frozen and stored at –20 °C. The samples after were thawed at room temperature, centrifuged at 5000 rpm in the cold. Mucin was precipitated using 6 units of Lydase per 1.0 ml of oral fluid by patented method (Patent Republic of Armenia No. 3295 A dated at May 16, 2019) [Yessayan L, Azatyan V, 2019]. The concentration of proinflammatory cytokine IL-2 and antiinflammatory IL- 4 was determined by the method of solid-phase enzyme-linked immunosorbent assay (ELISA) using the Vector-Best test systems (Vector-Best JSC, Novosibirsk, Russia) and was registered on a Statfax 303 Plus photometer (Awareness Technology, Inc. Palm City, FL 34990, USA).

Statistical analysis: Descriptive analysis (Mean ± SD for continuous and frequencies/proportion for categorical variables) were calculated for all variables of interest. Differences between two groups were evaluated using “chi-square” or “Fisher’s exact” tests for categorical variables and “Wilcoxon signed rank test” for continuous variables. Spearman correlation was performed for determination of relationships between continuous variables. P-value was considered significant at <0.05 and <0.001 for highly significant results. Analyses were conducted using Excel 2013 and R software software and program Vassar Stats to calculate odds ratio (OR) and 95% confidence intervals (CI).

RESULTS

The results of the clinical examination of the oral cavity, including the dental status of the oral mucosa and periodontium, are presented in Tables 1 and 2.

The frequency of detection of cracks in the corners of the mouth in the SHCV group was 53.1%, which was significantly and reliably higher than in the HHCV group ($p<0.001$). Disorders in the mucous membrane relief were observed in 91.7% of the SHCV group, which significantly exceeded the incidence of this indicator in HHCV patients ($p<0.001$). Hemorrhages on the buccal mucosa and hard palate were detected in 92.7% of the examined SHCV patients, which statistically differed significantly from the HHCV group ($p<0.001$). Examination of the tongue also revealed symptoms that were absent in the control group. The presence of coated on the surface of the tongue was found in 83.3% of the examined patients with SHCV, and foci of epithelial desquamation on the surface of the tongue were found in 19.8% ($p<0.001$).

Hyperemia and edema of the gums were observed with a high degree of reliability ($p<0.001$).

TABLE 1.

Clinical examination data on the oral mucosa in patients with Heated tobacco products and Cigarette smoking with Hepatitis C virus infection groups

| Sign | HHCV n=96 | | SHCV n=96 | | p-value* |
|---|--------------|------|--------------|------|----------|
| | n | % | n | % | |
| Cracks in the corners of the mouth | | | | | |
| Absent | 95 | 99 | 45 | 46.9 | <0.001 |
| Present | 1 | 1 | 51 | 53.1 | |
| Disorders in the mucous membrane relief | | | | | |
| Absent | 94 | 79.9 | 8 | 8.3 | <0.001 |
| Present | 2 | 2.1 | 88 | 91.7 | |
| Hemorrhages on the buccal mucosa and the hard palate | | | | | |
| Absent | 96 | 100 | 7 | 7.3 | <0.001 |
| Present | 0 | 0 | 89 | 92.7 | |
| Coated tongue | | | | | |
| Absent | 96 | 100 | 16 | 16.7 | <0.001 |
| Present | 0 | 0 | 80 | 83.3 | |
| Foci of epithelial desquamation on the surface of the tongue | | | | | |
| Absent | 96 | 100 | 77 | 80.2 | <0.001 |
| Present | 0 | 0 | 19 | 19.8 | |

Notes: * p-value test result from the comparison between HHCV and SHCV groups, SHCV – Cigarette smoking patients with Hepatitis C virus infection, HHCV- Heated tobacco users with Hepatitis C virus infection.

TABLE 2.

Clinical examination data on the oral mucosa in patients with Heated tobacco products and Cigarette smoking with Hepatitis C virus infection groups

| Sign | HHCV n=96 | | SHCV n=96 | | p-value* |
|--|--------------|------|--------------|------|----------|
| | n | % | n | % | |
| Hyperemia | | | | | |
| Absent | 95 | 99 | 28 | 29.2 | <0.001 |
| Present | 1 | 1 | 68 | 70.8 | |
| Cyanosis | | | | | |
| Absent | 71 | 74 | 63 | 65.6 | >0.308 |
| Present | 25 | 26 | 33 | 34.4 | |
| Edema | | | | | |
| Absent | 82 | 85.4 | 27 | 28.1 | <0.001 |
| Present | 14 | 14.6 | 69 | 71.9 | |
| Looseness of gingival papillae | | | | | |
| Absent | 95 | 99 | 79 | 82.3 | <0.005 |
| Present | 1 | 1 | 17 | 17.7 | |
| Bleeding | | | | | |
| Absent | 86 | 89.6 | 23 | 24 | <0.001 |
| Present | 10 | 10.4 | 73 | 73 | |
| Subgingival dental plaque | | | | | |
| Absent | 59 | 61.5 | 28 | 29.5 | <0.001 |
| Present | 37 | 38.5 | 67 | 70.5 | |
| Pathological gingival pockets more than 3.5 mm | | | | | |
| Absent | 84 | 87.5 | 24 | 25 | <0.001 |
| Present | 12 | 12.5 | 72 | 75 | |
| Purulent discharge from pathological gingival pockets | | | | | |
| Absent | 91 | 94.8 | 47 | 49 | <0.001 |
| Present | 5 | 9 | 49 | 51 | |

NOTES: (*) p-value test result from the comparison between HHCV and SHCV groups, SHCV – Cigarette smoking patients with Hepatitis C virus infection, HHCV- Heated tobacco users with Hepatitis C virus infection

in the group of patients with SHCV. The clinical picture of cyanosis was almost the same in both groups of observations and no statistical difference was observed ($p>0.308$). Looseness of gingival papillae in the group of patients with Cigarette smoking with Hepatitis C virus infection was observed in 17.7% of cases ($p<0.005$). Bleeding gums were observed in the main observation group in 73% of cases ($p<0.001$). Subgingival dental plaque was detected in 70.5% of patients in the main group ($p<0.001$). Pathological gingival pockets greater than 3.5 mm and purulent discharge from pathological gingival pockets in the Cigarette smoking with Hepatitis C virus infection group were detected in 75% vs 51% with a high degree of statistical significance ($p<0.001$).

The results of the microbiological study of the material obtained from the pathological gingival pockets showed that in the group of patients with HHCV, abundant growth of microorganisms was not observed in cultures of all the listed microorganisms, with the exception of *P. gingivalis* in 1 (2.2%) case ($OR=0.01$), which had a statistically significant difference ($p<0.001$) compared to the group of patients with SHCV. Abundant growth of microorganisms was observed in almost all patients in the SHCV group, namely: *P. gingivalis* was cultured in 41 (89.1%) cases ($OR=0.01$); *T. forsythia* – in 43 (93.5%) cases ($OR=0.01$); *E. corrodens* – in 40 (87%) cases ($OR=0.01$) and *A. actinomycetemcomitans* in 44 (95.7%) cases ($OR=0.01$), which had a statistically significant difference ($p<0.001$) in data compared to the HHCV group (Table 3).

An immunological study of the proinflammatory cytokine IL-2 and antiinflammatory cytokine IL-4 levels in oral fluid is presented in Table 4.

A comparative analysis of oral fluid cytokine levels in the HHCV and SHCV groups revealed that the level of the proinflammatory cytokine IL-2 in the SHCV group significantly increased by 9.04 times ($p<0.001$). The level of antiinflammatory IL-4 decreased sharply in the SHCV group by 71.5 times ($p<0.001$).

DISCUSSION

This small pilot study examined the effects of heated tobacco products and cigarette smoking on the oral mucosa and periodontium in patients with Hepatitis C virus infection. According to the literature, HSV, relative to heated tobacco products, has a lower

TABLE 3.

Microbial association of pathological gingival pockets in patients with Heated tobacco products and Cigarette smoking with Hepatitis C virus infection groups

| Microorganisms | Levels | HHCV | SHCV | OR | p-value* |
|---------------------------------|---------------|--------------|--------------|------|----------|
| | | n=46 n(%) | n=46 n(%) | | |
| <i>P. gingivalis</i> | $10^4 - 10^5$ | 45(100%) | 5(10.9%) | 1.21 | <0.001 |
| | $10^6 - 10^8$ | 1(2.2%) | 41(89.1%) | 0.01 | |
| <i>T. forsythia</i> | $10^4 - 10^5$ | 46(100%) | 3(6.5%) | 1.79 | <0.001 |
| | $10^6 - 10^8$ | - | 43(93.5%) | 0.01 | |
| <i>E. corrodens</i> | $10^4 - 10^5$ | 46(100%) | 6(13%) | 2.01 | <0.001 |
| | $10^6 - 10^8$ | - | 40(87%) | 0.01 | |
| <i>A. actinomycetemcomitans</i> | $10^4 - 10^5$ | 46(100%) | 2(4.3%) | 1.64 | <0.001 |
| | $10^6 - 10^8$ | - | 44(95.7%) | 0.01 | |

NOTES: (*) p-value test result from the comparison between HHCV and SHCV groups, OR- odds ratio, SHCV – Cigarette smoking patients with Hepatitis C virus infection, HHCV- Heated users with Hepatitis C virus infection.

TABLE 4. Oral fluid cytokine levels in patients with Heated tobacco products and Cigarette smoking with Hepatitis C virus infection groups (mean ± SD)

| Cytokines | HHCV (n=30) | SHCV (n=45) | OR/MD | 95% CI | p value* |
|-----------|----------------|----------------|--------|------------------|----------|
| IL2 | 2.75 ± 4.98 | 24.87 ± 18.01 | -22.12 | [-28.32; -17.85] | <0.001 |
| IL4 | 13.96 ± 25.84 | 0.2 ± 0.65 | 13.76 | [4.43; 23.93] | <0.001 |

NOTES: (*) *p*-value test result from the comparison between HHCV and SHCV groups MD- mean difference, OR- odds ratio, HHCV-heated tobacco users with HCV infection

content of potentially harmful and hazardous components and, therefore, a lower risk of developing smoking-related diseases compared to conventional cigarettes. To date, there are only a limited number of studies examining the effects of this alternative HSV on oral health, and further independent in vivo studies are needed [Kaur G et al., 2018; Sever E et al., 2023]. Currently, the global prevalence of conventional cigarette and HTP product use is higher among men. Awareness and use of Heated tobacco products products are steadily increasing. A large cross-sectional study of 7,714 people in Japan found that 5% of men and 2.2% of women used Heated tobacco products products. The authors concluded that young adults aged 20 to 30 years are more likely to smoke Heated tobacco products products than women and older adults. Our results partially support this conclusion, although in our study, 32.8% of women and 67.2% of men also use heated tobacco products products, the average age of which was 52.05 ± 12.25 years [Myagmar-Ochir E et al., 2021].

Cigarette smoking in patients with Hepatitis C virus infection has a negative impact on oral health, mucosal integrity, and periodontal disease. According to the literature, inhaled components cause inflammatory and structural changes in the oral epithelium, as well as histopathological changes [Zanetti F et al., 2017]. Our studies are partially consistent with the literature data, namely, in patients with Hepatitis C virus infection, cigarette smokers were found to have 92.7% hemorrhages on the buccal mucosa and the hard palate, disorders in the mucous membrane relief in the 91.7% cases. Among patients with Hepatitis C virus infection who smoked cigarettes, hyperemia was detected in 70.8% and bleeding gums in 73% of cases.

According to Sever E. et al. (2023) cigarette smoke can affect the quantity and quality of saliva, and data on the effect of long-term smoking on the

rate of saliva secretion are contradictory [Sever E et al., 2023]. Our study did not conduct research on the above-mentioned issue and does not have data for comparison.

Although several studies reported that cigarette smoking was associated with a higher incidence of Candida species and oral candidiasis, other studies, including the present

study, failed to find an association between oral Candida load, traditional cigarette smoking, and tobacco heating system [Vila et al., 2020]. Our results revealed with statistical significance from pathological gingival pockets in cigarette-smoking patients with HCV, abundant growth of *P. gingivalis* in 89.1%, *T. forsythia* in 93.5%, *E. corrodens* in 87%, and *A. actinomycetemcomitans* in 95.7% of cases.

Regarding the immunological study of oral fluid that we conducted in patients with Hepatitis C virus infection, there was no data in the literature for comparison with our study results.

One of the limitations of the study was that despite the fact that the Hepatitis C virus infection group had 192 participants only 75 of them from the Hepatitis C virus infection groups (cigarette smoking and heated tobacco products) agreed to pass the test of cytokines of the oral fluid, and microbiological study from the pathological gingival pockets 92 participants.

Another limitation was that the initial raw data from which the Excel database was created was a paper-based registry; and as the data were not double entered in the process of the data transmission errors could have happened.

CONCLUSION

The oral mucosa and periodontium status of Hepatitis C virus infection patients using the heated tobacco products system were significantly better than that of the patients Hepatitis C virus infection smoking cigarettes. In the Cigarette smoking patients with Hepatitis C virus infection group, periodontopathogenic microorganisms were observed in 100% of pathological gingival pockets cases. Further studies with larger sample sizes are needed to better understand the oral health of Hepatitis C virus infection patients.

REFERENCES

1. Ankily MA, Makkeyah F, Bakr MM, Mohamed Shamel M (2024). Evaluating the effects of cigarette smoking and heated tobacco products on hard dental tissues: a comparative histological and colorimetric analysis. *Clin Exp Dent Res.* 10(4): e941. DOI: 10.1002/cre2.941, 2024.
2. Azatyan VYu., Yessayan LK, Shmavonyan MV, Porksheyan K.A (2022). The characteristics of microbic landscape of the oral cavity in patients with viral hepatitis B, viral hepatitis C and HIV infection. *The New Armenian Medical Journal.* 16 (4): 82 -91. DOI: 10.56936/18290825-2022.16.4-79.
3. Calsina G, Ramon J-M, Echeverria J-J (2002). Effects of smoking on periodontal tissues. *J. Clin. Periodontol.* 29 (8): 771– 776. DOI: 10.1034/j.1600-051X.2002.290815.x.
4. Camoni N, Conti G, Esteves-Oliveira M, Carvalho TS, Andrea Rocuzzo A, Cagetti MG, Campus G (2023). Electronic Cigarettes, Heated Tobacco Products, and Oral Health: A Systematic Review and Meta-Analysis *Appl. Sci.* 13(17): 9654. DOI: 10.3390/app13179654.
5. Cohen JF, Ward KM, Gittleman J, Perez E, Pia T, Shuter J, Weinberger AH, Sulkowski M (2024). Hepatitis C and cigarette smoking behavior: themes from focus groups. *Nicotine Tob Res.* 26(8): 1029-1037. DOI: 10.1093/ntr/ntae032.
6. Czoli CD, White CM, Reid JL, Connor RJO, Hammond D (2020). Awareness and interest in IQOS heated tobacco products among youth in Canada, England and the USA. *Tob Control.* 29(1): 89-95. DOI: 10.1136/tobaccocontrol-2018-054654.
7. Haiduc A, Zanetti F, Zhao X, Schlage WK, Scherer M, Pluym N, et al. (2020). Analysis of chemical deposits on tooth enamel exposed to total particulate matter from cigarette smoke and tobacco heating system 2.2 aerosol by novel GC-MS deconvolution procedures. *J Chromatogr B Analyt Technol Biomed Life Sci.* 1: 1152: 122228. DOI: 10.1016/j.jchromb.2020.122228.
8. Iglesias-Sancho M, Llambí Mateos F, Salleras-Redonnet M (2020). Drug compounding for diseases of the oral mucosa. *Actas Dermosifiliogr (Engl Ed).* 1(10): 822-828. DOI: 10.1016/j.ad.2020.08.004.
9. Jiang X, Wu J, Wang J, Huang R (2019). Tobacco and oral squamous cell carcinoma: a review of carcinogenic pathways. *Tob Induc Dis.* 12: 17: 29. DOI: 10.18332/tid/105844.
10. Johnson NW, Bain CA (2000). Tobacco and oral disease. *EU-Working Group on tobacco and oral health. Br. Dent.* 189 (4): 200– 206. DOI: 10.1038/sj.bdj.4800721a.
11. Kakoei S, Nekouei AH, Kakoei S, Najafipour H (2021). The effect of demographic characteristics on the relationship between smoking and dry mouth in Iran: a cross-sectional, case-control study. *Epidemiol Health.* 43: e2021017. DOI: 10.4178/epih.e2021017.
12. Kaur G, Muthumalage T, Rahman I (2018). Mechanisms of toxicity and biomarkers of flavoring and flavor enhancing chemicals in emerging tobacco and non-tobacco products. *Toxicol Lett.* 15: 288: 143-155. DOI: 10.1016/j.toxlet.2018.02.025.
13. Kauss AR, Antunes M, Zanetti F, Hankins M, Hoeng J, Heremans A, van der Plas A (2022). Influence of tobacco smoking on the development of halitosis. *Toxicol. Rep.* 9: 316–322. DOI: 10.1016/j.toxrep.2022.02.012.
14. Kim SC, Friedman TC (2022). A new ingenious enemy: heat-not-burn products. *Tob Use Insights.* 15:1179173X221076419. doi: 10.1177/1179173X221076419.
15. Komar K, Glavina A, Boras VV, Verzak Z, Brailo V (2018). Impact of smoking on oral health: knowledge and attitudes of croatian dentists and dental students. *Acta Stomatol Croat.* 52(2): 148-155. DOI: 10.15644/asc52/2/8.
16. Kopa PN, Pawliczak R (2020). IQOS - A heat-not-burn (HnB) tobacco product-chemical composition and possible impact on oxidative stress and inflammatory response: A systematic review. *Toxicol Mech Methods.* 30: 81–87. DOI: 10.1080/15376516.2019.1669245.
17. Le Foll B, Piper ME, Fowler CD, Tonstad S, Bierut L, Lu L, Jha P, Hall WD (2022). Tobacco and nicotine use. *Nat Rev Dis Primers.*

- 8(1): 19. DOI: 10.1038/s41572-022-00346-w.
18. Luca A-C, Curpăn A-S, Iordache A-C, Mindru DE, Tarca E, Luca F-A, Paduret IA (2023). Cardiotoxicity of electronic cigarettes and heat-not-burn tobacco products - a problem for the modern pediatric cardiologist. *Healthcare*. 11(4): 491. DOI: 10.3390/healthcare11040491.
 19. Luo Z, Xue K, Zhang X, Lim JYC, Lai X, Young DJ, Zhang Z-X, Wu Y-L, Loh XJ (2020). Thermogelling chitosan-based polymers for the treatment of oral mucosa ulcers. *Biomater Sci*. 2020, 8(5): 1364-1379. doi: 10.1039/c9bm01754b.
 20. Moimaz SAS, Zina LG, Saliba O, Garbin CAS (2009). Smoking and periodontal disease: clinical evidence for an association. *Oral Health Prev. Dent*. 7(4): 369– 376.
 21. Myagmar-Ochir E, Kaneko M, Tomiyama K, Zaitso M, Watanabe S, Nishino Y, et al, (2021). Occupational difference in use of heated tobacco products: a cross-sectional analysis of retail workers in Japan. *BMJ Open* 2021, 11(e): 049395. DOI: 10.1136/bmjopen-2021-049395.
 22. Nazir MA, Al-Ansari A, Abbasi N, Almas K (2019). Global prevalence of tobacco use in adolescents and its adverse oral health consequences. *Open Access Maced J Med Sci*. 7(21): 3659-3666. DOI: 10.3889/oamjms.2019.542.
 23. Neuberger J (2021). Immunosuppression in gastroenterology and hepatology. *Best Pract Res Clin Gastroenterol*. 54-55: 101758. DOI: 10.1016/j.bpg.2021.101758.
 24. Owens VL, Ha T, Soulakova JN (2019). Widespread use of flavored e-cigarettes and hookah tobacco in the United States. *Prev Med Rep*. 22: 14: 100854. DOI: 0.1016/j.pmedr.2019.100854.
 25. Patil PB, Bathi R, Chaudhari S (2013). Prevalence of oral mucosal lesions in dental patients with tobacco smoking, chewing, and mixed habits: a cross-sectional study in South India. *J Family Community Med*. 20(2): 130-5. DOI: 10.4103/2230-8229.114777.
 26. Petrušić N, Posavac M, Sabol I, Mravak-Stipetić M (2015). The effect of tobacco smoking on salivation. *Acta Stomatol Croat*. 49: 309–315. DOI: 10.15644/asc49/4/6.
 27. Pouly S, Ng WT, Benzimra M, Soulan A, Blanc N, Zanetti F, Picavet P, Baker G, Haziza C (2021). Effect of switching to the tobacco heating system versus continued cigarette smoking on chronic generalized periodontitis treatment outcome: protocol for a randomized controlled multicenter study. *JMIR Res Protoc*. 10(1): e15350. DOI: 10.2196/15350.
 28. Ratajczak A, Jankowski P, Strus P, Feleszko W (2020). Heat not burn tobacco product-a new global trend: impact of heat-not-burn tobacco products on public health, a systematic review. *Int J Environ Res Public Health*. 17(2): 409. DOI: 10.3390/ijerph17020409.
 29. Saputri D, Abdillah N, Mutiara S, Basri G (2017). The correlation between pH and flow rate of salivary smokers related to nicotine levels labelled on cigarettes. *Dent. J*. 50: 61–65. DOI: 10.20473/j.djmk.v50.i2.p61-65.
 30. Saravia I, Pisinger C (2020). E-cigarettes, heat-not-burn and smokeless tobacco products. *Breathe (Sheff)*. 16(1): 161ELF. DOI: 10.1183/20734735.ELF161.
 31. Sever E, Božac E, Saltović E, Simonić-Kocijan S, Brumini M, Glažar I (2023). Impact of the tobacco heating system and cigarette smoking on the oral cavity: a pilot study. *Dent J (Basel)*. 11(11):251. DOI: 10.3390/dj11110251.
 32. Silva H (2021). Tobacco use and periodontal disease-the role of microvascular dysfunction. *Biology (Basel)*. 10(5): 441. DOI: 10.3390/biology10050441.
 33. Upadhyay S, Rahman M, Johanson G, Palmberg L, Ganguly K (2023). Heated tobacco products: insights into composition and toxicity. *ToxicCS*. 11(8):667. DOI: 10.3390/toxicCS11080667.
 34. Varghese J, Gharde PM (2023). A comprehensive review on the impacts of smoking on the health of an individual. *Cureus*. 15(10): e46532. DOI: 10.7759/cureus.46532.
 35. Vila T, Sultan AS, Montelongo-Jauregui D, Jabra-Rizk MA (2020). Oral candidiasis: a disease of opportunity. *J. Fungi (Basel)*. 6(1): 15. DOI: 10.3390/jof6010015.
 36. Vukas J, Mallock-Ohnesorg N, Rütther T, Pieper E, Romano-Brandt L, Stoll Y, et al, (2023). Two different heated tobacco products vs. cigarettes: comparison of nicotine

- delivery and subjective effects in experienced users. *Toxicol.* 11(6): 525. DOI: 10.3390/toxics11060525.
37. *Wiesmann-Imilowski N, Becker P, Gielisch MW, Ziebolz D, Vermehren F, Bitschnau M, et al, (2024).* Cytotoxic impact of nicotine products on periodontal ligament cells. *Clin Oral Investig.* 28(7): 399. DOI: 10.1007/s00784-024-05797-x.
38. *Willemsen MC, Croes EA, Kotz D, van Schayck OCP (2015).* Electronic cigarettes: use, health risks, and effectiveness as a cessation method [Article in Dutch]. *Ned Tijdschr Geneesk.* 159: A9259.
39. *World Health Organization (WHO) (2025).* World Hepatitis Alliance. Hepatitis C. 2025. Available online: <https://www.who.int/news-room/fact-sheets/detail/hepatitis-c>. Accessed 23 October, 2025.
40. *Ye P, Chen W, Huang F, Liu Q, Zhu YN, Wang X, Han XD, Wang WM (2021).* Smoking increases oral mucosa susceptibility to *Candida albicans* infection via the Nrf2 pathway: In vitro and animal studies. *J Cell Mol Med.* 25(16): 7948-7960. DOI: 10.1111/jcmm.16724.
41. *Yessayan LK, Azatyan Vyu (2019).* Method of precipitation of mucin in oral fluid. Patent RA No. 3295 A dated at May 16, 2019.
42. *Yoshioka T, Tabuchi T (2021).* Combustible cigarettes, heated tobacco products, combined product use, and periodontal disease: a cross-sectional JASTIS study. *PLoS One.* 16(3): e0248989. DOI: 10.1371/journal.pone.0248989.
43. *Zanetti F, Sewer A, Mathis C, Iskandar AR, Kostadinova R, Schlage WK, et al, (2016).* Systems toxicology assessment of the biological impact of a candidate modified risk tobacco product on human organotypic oral epithelial cultures. *Chem Res Toxicol.* 29(8): 1252-69. DOI: 10.1021/acs.chemrestox.6b00174.
44. *Zanetti F, Titz B, Sewer A, Lo Sasso G, Scotti E, Schlage WK, et al, (2017).* Comparative systems toxicology analysis of cigarette smoke and aerosol from a candidate modified risk tobacco product in organotypic human gingival epithelial cultures: A 3-day repeated exposure study. *Food Chem. Toxicol.* 101: 15-35. DOI: 10.1016/j.fct.2016.12.027.
45. *Zhang Y, He J, He B, Huang R, Li M (2019).* Effect of tobacco on periodontal disease and oral cancer. *Tob Induc Dis.* 9:17:40. DOI: 10.18332/tid/106187.
46. *Znyk M, Jurewicz J, Kaleta D (2021).* Exposure to heated tobacco products and adverse health effects, a systematic review. *Int J Environ Res Public Health.* 18(12): 6651. DOI: 10.3390/ijerph18126651.



CONTENTS

4. **DAS A.C., SAMIR P.V., KHAN S.H., FERNANDES B., ARYA A., MUSTAFA M.**
ARTIFICIAL INTELLIGENCE IN THERAPEUTIC DECISION-MAKING FOR COMPLEX DENTAL DISEASES: A REVIEW
11. **ALAM M.K. ALMOHAMMED Y.E.M., HAJEER M.Y., ALANAZI A.W.N., ALANAZI F.S.A., ALNAWMASI Y.M.F.**
LABORATORY ASSESSMENT OF CRISPR-MEDIATED MODULATION OF OSTEOBLASTIC AND OSTEOCLASTIC GENE EXPRESSION UNDER SIMULATED ORTHODONTIC FORCE
17. **GEORGE A.L., PANICKER P., FRANCIS F., RAGHUNANDANAN S., MOHIDEEN K., ALMUTAIRY M.F.**
CAR-T-INSPIRED IMMUNOMODULATORY NANOVESICLES FOR TARGETED ELIMINATION OF ORAL SQUAMOUS CELL CARCINOMA CELLS
23. **ALFAWZAN A.A., ALAM M.K., HAJEER M.Y.**
IN-VITRO EVALUATION OF NANOPARTICLE-REINFORCED ORTHODONTIC ADHESIVES FOR ENHANCED SHEAR BOND STRENGTH AND ANTIMICROBIAL ACTIVITY
30. **JADHAV S., PATRI G., BEHERA S.S.P., BANIK A., ARYA A., MUSTAFA M.**
STEM-CELL-DERIVED BIOENGINEERED DENTAL PULP CONSTRUCTS FOR VITAL PULP THERAPY: A RANDOMIZED LABORATORY TRIAL
36. **TUENKAR Y.A., SHANKARGOUDA S., SEHDEV B., SINGH R.B., RAMAMURTHY J., MAHAPATRA N.**
AI-GUIDED PERSONALIZED DRUG-DELIVERY NANOPARTICLES FOR PRECISION TREATMENT OF PERI-IMPLANTITIS: A MULTICENTER EVALUATION
42. **SADAT MANSOURI S., DADEHBEIGLOU P., NEMATI ANARAKI S., RAHMATPANAH K.**
CYANOACRYLATE VS. DENTIN BONDING ON REDUCING DENTAL SENSITIVITY
50. **JALALUDDIN M., CALIAPEROMAL S.K., JAYANTI I., PATIL M., RAMAMURTHY J., MUSTAFA M.**
MRNA-BASED REGENERATION OF PERIODONTAL LIGAMENT FIBROBLASTS: A TRANSLATIONAL PILOT STUDY
56. **AZATYAN V.YU., YESSAYAN L.K., SHMAVONYAN M.V., MURADYAN A.A.**
EVALUATING THE EFFECTS OF CIGARETTE SMOKING AND HEATED TOBACCO PRODUCTS ON THE ORAL MUCOSA AND PERIODONTIUM IN PATIENTS WITH HEPATIT C VIRUS IN ARMENIA: A PILOT STUDY
65. **MOHAMMADI E., NAZARBAGHI S., HAJIESMAELLO M.**
COMPARATIVE EFFICACY OF LOW-LEVEL LASER THERAPY AND TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION IN THE MANAGEMENT OF DIABETIC PERIPHERAL NEUROPATHY: A RANDOMIZED CONTROLLED TRIAL
73. **HOSSEINIAZAR M.M., KABOUDMEHRI M., ROOSTA Y.**
PREDICTIVE VALUE OF SERUM TRACE ELEMENTS FOR CHEMOTHERAPEUTIC EFFICACY IN GASTRIC AND COLON CANCER: A CROSS-SECTIONAL STUDY
82. **ESMAELZADEH M., ASHT'A'RI MEHRJARDI A., MOHAMMADINIA O., MOHAMMADPOUR S., HOKMABADI M.E., AMINI F., AZIZI T., VAKILI AHRARI RODI M.**
NEW HORIZONS IN SUBSTANCE ABUSE DISORDER: A SYSTEMATIC REVIEW OF EPIGENETIC MECHANISMS AND MULTIDIMENSIONAL PERSPECTIVES (2023–2025)
90. **SHAHROKHI-FARD P., SAGHEBI A., TALAEI A.**
EFFECTIVENESS OF ACCEPTANCE AND COMMITMENT THERAPY ON COVID-19 PROTECTION INDICATORS, PHYSICAL DISORDER SYMPTOMS, AND PERCEIVED STRESS IN HEALTHCARE PERSONNEL IN MASHHAD HOSPITALS
98. **SURKUNDA T.S., STANLEY W., ELENJICKAL V., BALLAL A., NAGARAJU S., BOPPE S., KAMATH N., SHASTRY B.**
CLINICAL FEATURES, OUTCOMES AND COMPARATIVE EVALUATION OF DIAGNOSTIC CRITERIA OF INVASIVE ASPERGILLOSIS AT A TERTIARY CARE CENTRE: A RETROSPECTIVE OBSERVATIONAL STUDY
- 108 **SABERI M.K., MOKHTARI H., HOSEINI AHANGARI S.A., OUCHI A., SHOURCHEH B.**
THE ONLINE ATTENTION TO SPIRITUAL HEALTH RESEARCH: AN ALTMETRIC ANALYSIS
- 118 **LETTER TO THE EDITOR**
A GENERALIZED ANALYTICAL REVIEW OF ARTICLES IN A ISSUE 2 ON ADVANCED TECHNOLOGIES IN MODERN STOMATOLOGY



The Journal is founded by
Yerevan State Medical
University after M. Heratsi.

Rector of YSMU

Armen A. *MURADYAN*

Address for correspondence:

Yerevan State Medical University
2 Koryun Street, Yerevan 0025,
Republic of Armenia

Phones:

(+37410) 582532 YSMU

(+37493) 588697 Editor-in-Chief

Fax: (+37410) 582532

E-mail: namj.ysmu@gmail.com, ysmiu@mail.ru

URL: <http://www.ysmu.am>

Our journal is registered in the databases of Scopus, EBSCO
and Thomson Reuters (in the registration process)



SCOPUS



EBSCO



THE GUFO

Print in "Monoprint" LLC
Director: Armen Armenakyan
Andraniks St., 96/8 Bulding
Yerevan, 0064, Armenia
Phone: (+37491) 40 25 86
E-mail: monoprint1@mail.ru

TheGufo is an online database platform designed to help researchers publish and share their scientific work on a global scale. Our company was founded to address the need for an affordable and user-friendly platform that removes many of the barriers traditionally imposed by the publishing industry.

All scientific work published through TheGufo complies with Creative Commons 4.0 and other recognized standards to ensure authenticity, proper referencing, and academic integrity. Each submission undergoes a detailed peer-review process prior to publication.

Our mission is to provide researchers worldwide with a professional, accessible, and cost-effective platform to share both new and existing work with their peers. To further encourage participation, we also offer special promotional programs for academic institutions.

Dear reader, to access our website, please follow the link below
<https://thegufo.com/> <https://>

Editor-in-Chief

Arto V. *ZILFYAN* (Yerevan, Armenia)

Deputy Editors

Hovhannes M. *MANVELYAN* (Yerevan, Armenia)

Hamayak S. *SISAKYAN* (Yerevan, Armenia)

Executive Secretary

Stepan A. *AVAGYAN* (Yerevan, Armenia)

Editorial Board

Armen A. *MURADYAN* (Yerevan, Armenia)

Drastamat N. *KHUDAVERDYAN* (Yerevan, Armenia)

Suren A. *STEPANYAN* (Yerevan, Armenia)

Foregin Members of the Editorial Board

Waleed *GHANIMA* (Oslo, Norway)

Carsten N. *Gutt* (Memmingen, GERMAY)

Ming-Hua *ZHENG* (Wenzhou, China)

Coordinating Editor (for this number)

Farzad *KARIMPOUR* (Yasuj, IR Iran)

Editorial Advisory Council

Vahe Yu. *AZATYAN* (Yerevan, Armenia)

Ara S. *BABLOYAN* (Yerevan, Armenia)

Ines *BANJARI* (Osijek, Croatia)

Azat A. *ENGIBARYAN* (Yerevan, Armenia)

Mahdi *ESMAEILZADEH* (Mashhad, IR Iran)

Ruben V. *FANARJYAN* (Yerevan, Armenia)

Gabriele *FRAGASSO* (Milano, Italy)

Samvel G. *GALSTYAN* (Yerevan, Armenia)

Armen Dz. *HAMBARDZUMYAN* (Yerevan, Armenia)

Airazat M. *KAZARYAN* (Oslo, Norway)

Seyran P. *KOCHARYAN* (Yerevan, Armenia)

Levon M. *MKRTCHYAN* (Yerevan, Armenia)

Ashot M. *MKRTUMYAN* (MoscowRussia)

Mariam R *MOVSIYAN* (Gumri, Armenia)

Mikhail Z. *NARIMANYAN* (Yerevan, Armenia)

Sevak *SHAHBAZYAN* (Yerevan, Armenia)

Arthur K. *SHUKURYAN* (Yerevan, Armenia)

Gevorg N. *TAMAMYAN* (Yerevan, Armenia)

Marine M. *TANASHYAN* (Moscow, Russia)

Hakob V. *TOPCHYAN* (Yerevan, Armenia)

Alexander *WOODMAN* (London, England)

Konstantin B. *YENKOYAN* (Yerevan, Armenia)

Yumei *NIU* (Harbin, China)

Peijun *WANG* (Harbin, Chine)